Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Specialty pharmaceutical firm Allergan is boosting its aesthetics portfolio through the acquisition of privately held Bonti. In exchange for $195 million up front, Allergan gets a pipeline of fast-acting neurotoxins, including a novel botulinium neurotoxin serotype E in Phase II studies for both aesthetic and therapeutic applications. Allergan sells cosmetic and therapeutic versions of the neurotoxin Botox, which generated a combined $3.1 billion in sales last year.
This article has been sent to the following recipient: